Live news related to LAKEFRONT BIOTHER. stock (BE0003818359): press releases, earnings publications, share price moves, analyst notes and corporate events. This page is auto-updated whenever new financial information is available.
The latest financial news on LAKEFRONT BIOTHER. mainly cover M&A activity, earnings publications et the annual general meeting. The stock trades at €24,24 on Euronext Paris, down 0,49% at the last update. This page lists the articles published on LAKEFRONT BIOTHER. stock to track the share price, company announcements and any item likely to influence market perception.
Lakefront Biotherapeutics announced on Monday the appointment of Eric Hedrick, MD, as Medical Director. This new role is part of the strategic restruc…
Galapagos has revealed its Q1 2026 results, marked by a significant contraction in revenue and operational expenses. The company, which is renaming it…
Galapagos NV has announced a binding framework agreement with Gilead Sciences concerning Gilead's acquisition of Ouro Medicines. This agreement struct…
Galapagos NV has released its 2025 annual report and announced a joint ordinary general meeting and extraordinary general meeting scheduled for April …
On March 23, 2026, Galapagos announced that it was in advanced discussions with Gilead Sciences to establish a strategic partnership involving OM336 (…
On March 5, 2026, Galapagos NV announced the appointment of Tania Philipp as Chief Human Resources Officer (CHRO), effective from March 4, 2026. Tania…
On Monday, biotechnology group Galapagos released its financial results for the year 2025, marked by a dramatic recovery in net income due to the rele…
Galapagos NV has announced the appointment of Dr. Paulo Fontoura as an independent non-executive director to its board, effective from February 9, 202…
The biotechnology group Galapagos announced on January 5th the decision of its board of directors to commence the closure of its cell therapy operatio…
Belgian laboratory Galapagos announced on December 18 the results of two phase 3 studies evaluating its selective TYK2 inhibitor, GLPG3667. The trial …
